Osteoboost Health announced the nationwide availability of Osteoboost, the first and only FDA-cleared prescription medical device for low bone density.
Osteoboost is a brand-new wearable that bridges the gap between next-generation consumer health technology and rigorously tested medical innovation. Designed for effortless, at-home use, this clinically proven device delivers targeted vibration therapy directly to the spine and hips: areas at high risk for osteoporotic fractures.
Related: Avvio Medical treats first patients with innovative kidney stone therapy
CEO Laura Yecies said, “Osteoboost empowers people to lead longer, stronger, and more active lives. While the belt is sophisticated medical technology rigorously tested and validated for efficacy, the treatment is easy – 30 minutes a day of vibration therapy that can be done while walking, or other activities.”
A gold-standard, double-blinded, placebo-controlled clinical trial at the University of Nebraska Medical Center demonstrated that Osteoboost slowed bone density and strength loss in postmenopausal women with osteopenia who used it at least 3 times per week:
- 85% reduction in the loss of bone density in the spine
- 83% reduction in the loss of bone strength in the spine
- 55% reduction in the loss of bone density in the hip
“It’s been a long time since we’ve seen any innovation for bone health, and yet every day I see patients terrified of the risks they face just walking down the street,” said Dr. Yevgeniya Kushchaeva, Clinical Director of University of South Florida Health Adult Endocrinology, and Medical Director of Adult Osteoporosis Program. “Osteoboost did this the right way. They spent years investing in the clinical trial and FDA approval processes – not easy even for larger pharmaceutical companies.”
Osteoboost also announced new strategic investments from AARP, Harvard Business School Angels, and She’s Independent, plus a follow-on investment from Esplanade Healthtech Ventures.
